ABUS vs MPC · P/E 5.4, rev $6.2M vs P/E 16, rev $138.86B
Arbutus Biopharma Corp (ABUS) versus Marathon Petroleum Corp (MPC) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Marathon Petroleum Corp (MPC) is a oil & gas refining & marketing company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported MPC revenue for 2024-12-31 was $138.86B. Net income was $5.07B. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MPC currently screens at market cap $71.41B and trailing P/E 16.1.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. MPC currently screens at market cap $71.41B and trailing P/E 16.1.
Not investment advice. Open the ABUS and MPC stock pages for the full models.
Not investment advice.